Bli medlem
Bli medlem

Du är här


Medical Prognosis Institute: MPI - publishes positive results with DRP(TM) tool in gastroesophageal cancer

Hoersholm; February 17, 2016 - Medical Prognosis Institute A/S (MPI.CO)
(Denmark and Phoenix, AZ, USA) announced today that MPI, in collaboration
with Aarhus University Hospital, in the online journal PLOS ONE publishes
positive results of a clinical test of its Drug Response Predictor (DRP(TM))
technology in patients with gastroesophageal cancer.

Based on a pre-treatment biopsy, the DRP(TM) was able to correctly predict
retrospectively which patients would benefit from standard chemotherapy. "The
miRNA profile predictive for sensitivity to cisplatin, epirubicine and
capecitabine was shown to be independently associated with overall survival
and disease-specific survival in patients with gastro-esophageal cancer," the
conclusion reads.

"This is a further validation of the Drug Response Predictor - DRP(TM)-
technology, building on microRNA, which was recently granted a patent in
Australia. We are diligently building on strengthening data for the clinical
relevance of the DRP(TM) for the use in personalized medicine,"

Said Adjunct professor Peter Buhl Jensen, MD, PhD and CEO of MPI


Link to the publication:

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop
tumor-derived gene signatures that may predict which cancer patients are
highly likely responders to a given anticancer product. The DRP(TM) has been
tested in 37 trials, where 29 trials showed that drug-specific DRP(TM)
Biomarkers could predict which patients had a positive effect of the
treatment. The DRP(TM) platform has also been externally validated and
published in collaboration with leading statisticians at the MD Anderson
Cancer Center. The DRP(TM) method can be used to design the Clinical
Development Plan, i.e. to select which indications are relevant for a given
anticancer drug. Further to and in addition to this, individual patients'
gene patterns can be analyzed as part of a screening procedure for a clinical
trial to ensure inclusion of those patients who have a high likelihood of
response to the drug. This DRP(TM) method builds on the comparison of
sensitive and resistant human cancer cell lines including genomic information
from cell lines combined with clinical tumor biology and clinical correlates
in a systems biology network. MicroRNA is used on certain products whereas
the messenger RNA is more broadly useable and more validated. The DRP(TM)
platform can be used in all cancer types and has been patented for more than
60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with
cancer drug developers to apply its DRP(TM) diagnostic platform to streamline
and de-risk clinical trials and drug development via biomarker optimization,
patient stratification, and development of companion diagnostics.

For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD
Phone: +45 21 60 89 22

Certified Advisor:

Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup,

Positive results with DRP(TM) tool in gastroesophageal cancer


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.